Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)--a diagnostic and therapeutic challenge

Area of Science:

• Immunology
• Genetics
• Endocrinology

Background:

• Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED), or autoimmune polyendocrine/polyglandular syndrome type 1 (APS1), is a rare autoimmune disorder.
• It results from mutations in the autoimmune regulator (AIRE) gene, leading to a lack of active AIRE protein crucial for self-tolerance.
• APECED presents with a variable phenotype, including the classic triad of mucocutaneous candidosis, hypoparathyroidism, and adrenal failure, alongside potentially life-threatening complications.

Purpose of the Study:

• To highlight the diagnostic challenges of APECED due to its variable presentation.
• To introduce and evaluate a novel diagnostic tool for APECED.
• To emphasize the need for regular clinical follow-up for APECED patients.

Main Methods:

• Review of clinical diagnostic criteria for APECED.
• Investigation of autoantibodies against interferon-omega as a diagnostic marker.
• Exclusion of thymoma and myasthenia gravis in diagnostic considerations.

Main Results:

• The clinical course of APECED is unpredictable, necessitating vigilant patient monitoring.
• Diagnosis can be challenging in early stages, as the clinical picture may not be immediately suggestive of APECED.
• Autoantibody testing against interferon-omega demonstrates high specificity and sensitivity for APECED diagnosis, surpassing gene analysis in certainty when other conditions are excluded.

Conclusions:

• Regular clinical follow-up by experienced physicians is essential for managing APECED patients.
• Autoantibodies against interferon-omega represent a highly reliable diagnostic tool for APECED.
• Early and accurate diagnosis of APECED is critical for managing its potentially severe manifestations.